Animas Corporation manufactures and distributes insulin delivery and glucose management systems for people with diabetes throughout the world. The company offers insulin pumps, pump supplies, infusion sets, skins, and cases and other accessories. Its products also include OneTouch Ping, a glucose management system; Animas Vibe, a continuous glucose monitoring-enabled insulin pump system; and SEVEN PLUS Continuous Glucose Monitoring System, a glucose monitoring device for detecting trends and tracking patterns in adults with diabetes. In addition, the company provides offers ezManager Max, a diabetes management software solution; and Diasend, a Web-based diabetes management system that allows...
200 Lawrence Drive
West Chester, PA 19380
Founded in 1996
Animas Corporation Announces Positive Results from the Second Phase of Human Clinical Trials
Feb 28 13
Animas Corporation announced positive results from the second phase of human clinical trials of a first-generation, closed-loop insulin delivery system in development, designed to predict a rise or fall in blood glucose and correspondingly increase, decrease, suspend and resume insulin delivery. The data were presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Paris, France. The feasibility study of the predictive Hypoglycemia-Hyperglycemia Minimizer (HHM) System in development was conducted in 20 adults with Type 1 diabetes and designed to investigate the System's ability to adjust insulin dosing to proactively mitigate hypoglycemia and hyperglycemia. The study, which was the first conducted in humans to investigate the configuration of the predictive algorithm, revealed differences in the algorithm's insulin-dosing characteristic and provided insights into the sensitivity of the System. The results also indicated that the System reduced insulin delivery in advance of hypoglycemia and triggered timely warnings. The study was conducted by Animas Corporation in partnership with leading academic research institutions, including the University of California, Santa Barbara; Sansum Diabetes Research Institute; and the Center for Diabetes Technology at the University of Virginia. The study investigated the effect of a fundamental algorithm parameter on the quantitative insulin-dosing characteristics of the System. The parameter, known as the 'aggressiveness factor', affects how readily the algorithm adjusts insulin delivery in response to glucose fluctuations. This is the first study in humans to investigate tuning such an algorithm parameter. The results demonstrated differences in the algorithm's insulin-dosing characteristics based on three aggressiveness factors and reinforced the importance of investigating the sensitivity of the System to its key parameters. The study also investigated the predictive, proactive methods by which the System mitigates hypoglycemia, especially as compared to reactive, threshold-based systems. In particular, two predictive hypoglycemia safeguards of the System were investigated: its ability to decrease/suspend insulin delivery before a hypoglycemic threshold is reached, and its ability to trigger timely alerts for imminent hypoglycemia. The results indicated that the System reduced insulin delivery in advance of breaches of a hypoglycemic threshold and triggered timely warnings for imminent hypoglycemia.